Abiraterone and increased survival in metastatic prostate cancer - Wikidata - wikimedia - TriplyDB

Abiraterone and increased survival in metastatic prostate cancer

Abiraterone and increased survival in metastatic prostate cancer

http://www.wikidata.org/entity/Q29617512

about

Emerging molecularly targeted therapies in castration refractory prostate cancer Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001 Abiraterone in metastatic prostate cancer without previous chemotherapy Immunobiology and immunotherapy in genitourinary malignancies Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer Galeterone for the treatment of advanced prostate cancer: the evidence to date CYP17 inhibitors in prostate cancer: latest evidence and clinical potential A Perspective of Immunotherapy for Prostate Cancer Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer Androgen Receptor Structure, Function and Biology: From Bench to Bedside Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysis Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer Sequence of treatment in locally advanced and metastatic renal cell carcinoma Mechanisms of resistance in castration-resistant prostate cancer (CRPC)Persistent androgen receptor addiction in castration-resistant prostate cancer Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer Single-cell analyses of circulating tumor cells Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy Targeting molecular resistance in castration-resistant prostate cancer ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies Immune Infiltration and Prostate Cancer Progress of molecular targeted therapies for prostate cancers Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy Renin-angiotensin system blockade: Its contribution and controversy Abiraterone in prostate cancer: a new angle to an old problem Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy Immunotherapy for prostate cancer: recent developments and future challenges Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Circulating tumors cells as biomarkers: progress toward biomarker qualification Dynamic changes in numbers and properties of circulating tumor cells and their potential applications

P2860

Q21284745-3DA7EDE3-5A71-459B-8FCB-7CDD350662C5 Q24302773-7578A984-B5F5-42BC-9E4C-18138D77C9FC Q24612084-02725DEF-4B70-43B8-8A10-C7086FE899AA Q26738668-BDA60737-F593-48E2-8C2B-E434DA88EC0D Q26739708-CB0D6AE0-F381-4A55-A87D-EEAD68F3028C Q26739887-4F4FCCE7-1611-4FC2-8A80-E38078B91CDF Q26740070-C78CF34B-491E-4631-8FDE-7AC3B6D440A8 Q26741277-8ACE828C-4F30-4CF6-BDF0-92FF7D0001FE Q26746524-99C99A52-A973-463D-9E43-B25E04AD0F12 Q26747699-CAB012D7-6A9A-47AA-AA92-FDB5AFC16DC6 Q26747782-6B08ACDD-54AF-4B10-8467-61F3E44C2EA7 Q26750620-D4CF0F44-F8C2-4140-9B72-C8C84CFB1BEB Q26750866-F2EDFCAD-2335-4D4E-AB2B-19BE30F6857C Q26751237-1B721AFA-679E-4B47-BA43-7E3DE8249D46 Q26766638-17C9A5ED-3D0C-477C-8DED-36BED4D2F171 Q26770428-8AFE2535-548F-492B-BF5E-893E9FD08CFC Q26772883-170081B8-8570-4326-B252-CB6122D96FB1 Q26773406-F684E91B-537A-484D-BCFB-1B5804F54677 Q26773634-5019A282-E6D9-4819-82B4-E1F9A063267E Q26773653-1C5DB2BF-5398-4F9C-ACF2-ECD60E676AFF Q26774221-8A0CC93C-6DEB-41E9-966C-2E5024F1B57B Q26777163-F90B47BB-67C7-4042-A569-B4B813BD0A2C Q26777310-01320DB7-4922-40A2-A314-6253DFCB3AF6 Q26778816-749563AA-154C-44AA-A2C6-6A6C04E85A77 Q26783861-915FF6B8-C4D7-48AE-9B3D-9F0DCAB08338 Q26786543-087EABCF-4914-4DC0-8884-0138088F31D5 Q26795445-047CB994-A4CB-4E3F-862C-5E96CEE98B25 Q26796568-1209B3DC-AB9F-49A0-B77D-C64B3633D290 Q26796704-10B27FF9-DF17-46F0-A490-516275DC4411 Q26798412-F4B0E3F8-8C60-4E7A-814F-E0F538954E53 Q26823014-1CE138E4-AD02-4351-AF4F-7DBD86370F9B Q26825053-5D2F506F-9DB4-4369-B255-BACED66BD892 Q26827221-6CB4B336-2F14-460A-A29A-51D08EB8B546 Q26828810-2AB0F1AB-2B05-4EF3-9D81-D4F51F85584C Q26851177-A50A8418-1618-4F69-A213-CC5538482E5F Q26851608-7B7093F2-7BF9-46D3-8360-94810929756F Q26852388-3B08B3DD-2684-4B9E-BA7B-F2F2165BC60B Q26852544-65941856-9C9A-489E-AE5B-79533D8A089B Q26852579-CFD44152-B37A-4829-A5D4-7459BB631BB0 Q26853569-A0640F42-EB4A-4244-AECA-8641D517677F

P2860

Abiraterone and increased survival in metastatic prostate cancer

http://www.wikidata.org/entity/Q29617512

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Abiraterone and increased survival in metastatic prostate cancer

@ast

Abiraterone and increased survival in metastatic prostate cancer

@en

type

label

Abiraterone and increased survival in metastatic prostate cancer

@ast

Abiraterone and increased survival in metastatic prostate cancer

@en

prefLabel

Abiraterone and increased survival in metastatic prostate cancer

@ast

Abiraterone and increased survival in metastatic prostate cancer

@en

P1433

Q29617512-8E44F98F-A394-4F24-A299-C44519CE57B4

P1476

Q29617512-11079A9A-97FB-4D12-B923-2A3F82E0A34A

P2093

Q29617512-0A435A62-271B-417E-A4FE-1C38E9D0C140

Q29617512-0AEF21D8-C6D9-42A4-83F8-4F775140D8A7

Q29617512-10469006-2F06-438C-88C2-82E92EA78646

Q29617512-1AB15F11-1871-4426-9F6D-5CE55304324F

Q29617512-1C52B653-57B2-4E43-BF1F-1DDBD6C83190

Q29617512-1DE213FE-7B01-4303-A557-37FFC0FF9964

Q29617512-1E58BFC8-498F-47FE-A5AD-F834C7E1FCB0

Q29617512-2791B75B-06A6-4445-BB10-94EFECF64313

Q29617512-32134C69-BDAD-474D-BA33-99C89DEEF182

Q29617512-34AFB818-9485-4A53-8E04-793133842374

P2860

Q29617512-0133EC44-B93E-4B64-A2B9-727F7F65D7D0

Q29617512-029C4678-FB5B-4604-8F75-0EAA7472D609

Q29617512-0B4E6DD5-811B-412A-81EF-4557B5BABF3E

Q29617512-1705ACFD-4C51-4A50-A940-A9A0EFFE6661

Q29617512-1E21D16C-4B97-43D5-B3CE-677881040BAD

Q29617512-4366AFAD-30F0-446B-98DA-686CA3B96954

Q29617512-475B18D4-55E0-40F6-8D9A-C4E3D29FE55E

Q29617512-47FED51F-1915-4098-97CF-60A0A76CDAB1

Q29617512-5A6A3DAE-805C-4A0A-9DC7-8F5ED5E8791C

Q29617512-5B041AE2-27DD-4AEC-B4A6-AFA4F5372A91

P304

Q29617512-7E8D3BDF-F444-4618-8EB3-22C10B246006

P31

Q29617512-00415084-1D24-4D7D-B44A-FC950B8248B2

P3181

Q29617512-9323FCB1-54E6-46F4-AA51-BD9D90A96789

P356

Q29617512-167171F9-0152-4064-BA32-9502A6162804

P407

Q29617512-FE95CA6E-E513-4D21-9CE8-89F668E418BC

P433

Q29617512-E1FB91C1-D1D4-44A9-9042-6086FFED34F4

P478

Q29617512-9EC5CFD8-547B-46A7-9909-354F9AFA6CC8

P50

Q29617512-3EAAC098-5320-4032-9ADF-C53D5EA95205

P5008

Q29617512-DE1A55D5-34EE-4ED6-9D0F-D6AB1AA1E463

P577

Q29617512-B7D244B1-CE06-4E55-82EF-0E5221158E3B

P698

Q29617512-8BFE904F-0ADC-4B76-A059-2DADE2E77CD9

P921

Q29617512-27d080db-4425-7400-801b-6ee9366f192c

Q29617512-bdf8d48e-4733-ba49-0823-feaf59e4ed78

P932

Q29617512-547D75DB-5868-4EF8-BF39-D840B9330C8F

P3181

P356

P1433

The New England Journal of Medicine

P1476

Abiraterone and increased survival in metastatic prostate cancer

@en

P2093

Andrea Zivi

http://www.w3.org/2001/XMLSchema#string

Arturo Molina

http://www.w3.org/2001/XMLSchema#string

Aude Fléchon

http://www.w3.org/2001/XMLSchema#string

COU-AA-301 Investigators

http://www.w3.org/2001/XMLSchema#string

Charles J Ryan

http://www.w3.org/2001/XMLSchema#string

Christopher J Logothetis

http://www.w3.org/2001/XMLSchema#string

Christopher M Haqq

http://www.w3.org/2001/XMLSchema#string

Cora N Sternberg

http://www.w3.org/2001/XMLSchema#string

Diletta Bianchini

http://www.w3.org/2001/XMLSchema#string

Eleni Efstathiou

http://www.w3.org/2001/XMLSchema#string

P2860

The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Molecular determinants of resistance to antiandrogen therapy

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

P304

1995-2005

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

266674

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1014618

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

364

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21612468

http://www.w3.org/2001/XMLSchema#string

P921

metastatic prostate carcinoma

P932

3471149

http://www.w3.org/2001/XMLSchema#string